Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed and treated in advanced tumor stages with poor prognosis. More effective screening programs and novel therapeutic means are urgently needed. Recent studies have regarded tight junction protein claudin 18.2 (CLDN18.2) as a ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xi, Zhang, Cheng-Sheng, Dong, Xu-Yuan, Hu, Yuan, Duan, Bao-Jun, Bai, Jun, Wu, Yin-Ying, Fan, Lin, Liao, Xin-Hua, Kang, Ye, Zhang, Peng, Li, Meng-Yang, Xu, Jiao, Mao, Zhi-Jun, Liu, Hui-Tong, Zhang, Xiao-Long, Tian, Li-Fei, Li, En-Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Basic Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305579/
https://www.ncbi.nlm.nih.gov/pubmed/36051096
http://dx.doi.org/10.4251/wjgo.v14.i7.1252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305579/
https://www.ncbi.nlm.nih.gov/pubmed/36051096
http://dx.doi.org/10.4251/wjgo.v14.i7.1252

Ejemplares similares